In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on Agilent (NYSE: A), with a price target of $86. The company’s shares closed yesterday at $69.41.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.6% and a 64.6% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and NanoString Tech.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agilent with a $80 average price target, representing a 15.3% upside. In a report issued on October 3, Cowen & Co. also reiterated a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
Agilent’s market cap is currently $22.14B and has a P/E ratio of 76.27. The company has a Price to Book ratio of 4.85.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock. Last month, Heidi Fields, a Director at A sold 5,482 shares for a total of $371,296.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates through the following segments: Life Sciences & applied markets; Diagnostics & Genomics; and Agilent CrossLab Business.
